Business:
CD8 Treg cell modulators
Drug notes:
2 additional undisclosed programs RD/Clin0 undisclosed
About:
Mozart Therapeutics is a Seattle-based biopharmaceutical company focused on developing disease-modifying therapies for autoimmune and inflammatory diseases. They aim to modulate the immune system, specifically focusing on a specific subset of CD8 T cells. Their approach utilizes regulatory CD8 T cell modulators, molecules designed to target and activate these specific regulatory CD8 T cells. These cells play a critical role in self-tolerance, and a defective regulatory network leads to tissue destruction. Activation of regulatory CD8 T cells is intended to restore immune balance and prevent the excessive inflammatory response seen in autoimmune diseases, therefore halting, or preventing tissue damage. Some of their programs target autoimmune-mediated gastrointestinal disease.